{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:21:15Z","timestamp":1783405275876,"version":"3.54.6"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Vitiligo is a chronic autoimmune disease that can manifest at any age and affect any anatomical site. Clinically characterized by hypopigmented or depigmented macules and patches on the skin and mucous membranes, and occasionally accompanied by leukotrichia, the condition imposes a profound psychosocial burden and significantly impairs patients\u2019 quality of life. Although conventional therapeutic modalities\u2014including corticosteroids, topical calcineurin inhibitors, phototherapy, and surgical interventions\u2014can achieve varying degrees of disease control, their long-term efficacy is frequently constrained by the chronic, relapsing, and unpredictable nature of the disease.Recently, a deeper understanding of the pathogenesis of vitiligo has highlighted the substantial therapeutic potential of small-molecule targeted agents, particularly Janus kinase (JAK) inhibitors. Emerging evidence from clinical trials and case reports corroborates the efficacy of specific JAK inhibitors in promoting the repigmentation of lesional skin. This review synthesizes current research concerning the mechanisms of action, clinical applications, and safety profiles of representative JAK inhibitors\u2014namely ruxolitinib, upadacitinib, and abrocitinib\u2014in the management of vitiligo, aiming to provide novel insights for future therapeutic strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1868416","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:48:02Z","timestamp":1783403282000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Janus kinase inhibitors for vitiligo"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinyu","family":"Wen","sequence":"first","affiliation":[{"name":"Department of Dermatology, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5005\/jp\/books\/12775_12","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-2667(24)00026-4","article-title":"Estimating the burden of vitiligo: a systematic review and modelling study","volume":"9","author":"Akl","year":"2024","journal-title":"Lancet Public Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.2787","article-title":"Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study","volume":"159","author":"Bibeau","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000506103","article-title":"Vitiligo: a review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19451","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force part 1: towards a new management algorithm","volume":"37","author":"van Geel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cytogfr.2024.11.002","article-title":"JAK inhibitors in immune regulation and treatment of vitiligo","volume":"80","author":"Liu","year":"2024","journal-title":"Cytokine Growth Factor Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17627","article-title":"Segmental vitiligo: autoimmune pathogenesis, neuronal mechanisms, and somatic mosaicism","volume":"64","author":"Lin","year":"2025","journal-title":"Int J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.12.009","article-title":"Segmental vitiligo: a distinct entity with unique pathogenesis and clinical implications","volume":"146","author":"Shen","year":"2026","journal-title":"J Invest Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.11","article-title":"Segmental vitiligo as the possible expression of cutaneous somatic mosaicism: implications for common non-segmental vitiligo","volume":"21","author":"Taieb","year":"2008","journal-title":"Pigment Cell Melanoma Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00752-6","article-title":"Vitiligo treatments: review of current therapeutic modalities and JAK inhibitors","volume":"24","author":"Cunningham","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bjd.20596","article-title":"British Association of Dermatologists guidelines for the management of people with vitiligo 2021","volume":"186","author":"Eleftheriadou","year":"2022","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3680","article-title":"Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants","volume":"48","author":"Jin","year":"2016","journal-title":"Nat Genet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2016.00003","article-title":"Genetic susceptibility to vitiligo: GWAS approaches for identifying vitiligo susceptibility genes and loci","volume":"7","author":"Shen","year":"2016","journal-title":"Front Genet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3390\/cells12060936","article-title":"The role of oxidative stress in vitiligo: an update on its pathogenesis and therapeutic implications","volume":"12","author":"Chang","year":"2023","journal-title":"Cells"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.65","article-title":"Melanocytes as instigators and victims of oxidative stress","volume":"134","author":"Denat","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12469795","article-title":"In vitro growth characteristics of melanocytes obtained from adult normal and vitiligo subjects","volume":"88","author":"Puri","year":"1987","journal-title":"J Invest Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102859","article-title":"Th1-like Treg in vitiligo: an incompetent regulator in immune tolerance","volume":"131","author":"Chen","year":"2022","journal-title":"J Autoimmun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900027","article-title":"The role of memory CD8(+) T cells in vitiligo","volume":"203","author":"Riding","year":"2019","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.autrev.2016.01.004","article-title":"The role of IL-17 in vitiligo: a review","volume":"15","author":"Singh","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2503924","article-title":"Transcriptome analysis and emerging driver identification of CD8+ T cells in patients with vitiligo","volume":"2019","author":"Deng","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.618897","article-title":"Pathophysiology of skin resident memory T cells","volume":"11","author":"Tokura","year":"2020","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.26226\/morressier.595a9c57d462b80296c9fe01","article-title":"Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3","volume":"138","author":"Boniface","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.21417\/b76k56","article-title":"CD49a expression defines tissue-resident CD8(+) T cells poised for cytotoxic function in human skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.3390\/ijms21103552","article-title":"The role of T(RM) cells in the pathogenesis of vitiligo-a review of the current state-of-the-art","volume":"21","author":"Fraczek","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"eaam7710","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci Transl Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.335","article-title":"Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients","volume":"135","author":"Regazzetti","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.4280","article-title":"Inflammatory bowel disease therapy: blockade of cytokines and cytokine signaling pathways","volume":"34","author":"Yamamoto-Furusho","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B30","doi-asserted-by":"publisher","first-page":"11429","DOI":"10.3390\/ijms222111429","article-title":"Role of cytokines in vitiligo: pathogenesis and possible targets for old and new treatments","volume":"22","author":"Custurone","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus kinase family in autoimmune skin diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12949","article-title":"An update on vitiligo pathogenesis","volume":"34","author":"Seneschal","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2016.11.014","article-title":"Vitiligo pathogenesis and emerging treatments","volume":"35","author":"Rashighi","year":"2017","journal-title":"Dermatol Clin"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.09.016","article-title":"Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease","volume":"137","author":"Richmond","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: mechanisms of pathogenesis and treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: a review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.540","article-title":"A quantitative increase in regulatory T cells controls development of vitiligo","volume":"134","author":"Chatterjee","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/9781444394016.ch3","article-title":"Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis","volume":"13","author":"Mesa","year":"2010","journal-title":"IDrugs"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.047","article-title":"Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: descriptive subgroup analyses from a phase 2, randomized, double-blind trial","volume":"86","author":"Hamzavi","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01381-7","article-title":"Efficacy and safety of ruxolitinib cream in vitiligo by patient characteristic subgroups: descriptive pooled analysis from two phase 3 studies","volume":"15","author":"Seneschal","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.023","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B","volume":"78","author":"Joshipura","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf485","article-title":"Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study","volume":"194","author":"Harris","year":"2026","journal-title":"Br J Dermatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.70049","article-title":"Effectiveness and safety of ruxolitinib cream 15 mg\/g in patients with non-segmental vitiligo: A real-life study","volume":"65","author":"Cristallo","year":"2026","journal-title":"Int J Dermatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.02.087","article-title":"Clinical efficacy and safety analysis of 1.5% ruxolitinib cream in the treatment of facial vitiligo in adolescents: A retrospective study of 74 cases","author":"Chen","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.02.077","article-title":"Targeted synergy for vitiligo in refractory areas: A real-world study of ruxolitinib cream combined with 308-nm excimer lamp","author":"Zhang","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.645","article-title":"Addition of narrow-band UVB phototherapy to ruxolitinib cream in patients with vitiligo","volume":"142","author":"Pandya","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jdcr.2024.02.034","article-title":"Case series of topical 1.5% ruxolitinib cream for pediatric vitiligo","volume":"54","author":"Meister","year":"2024","journal-title":"JAAD Case Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.11.002","article-title":"Topical ruxolitinib for treatment-induced vitiligo in a patient with metastatic melanoma","volume":"55","author":"Tasdogan","year":"2025","journal-title":"JAAD Case Rep"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2025.08.016","article-title":"Topical 1.5% ruxolitinib cream for facial refractory segmental vitiligo: A retrospective single-center study","volume":"24","author":"Huang","year":"2026","journal-title":"JAAD Int"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2025.01.016","article-title":"Repigmentation of vitiligo with 5-fluorouracil tattooing in combination with topical ruxolitinib: A case report","volume":"58","author":"Macit","year":"2025","journal-title":"JAAD Case Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106362","article-title":"Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders","volume":"183","author":"Roskoski","year":"2022","journal-title":"Pharmacol Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102655","article-title":"Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"73","author":"Passeron","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.12.036","article-title":"Three-dimensional imaging for facial vitiligo: Results from a phase 2 randomized controlled trial investigating upadacitinib in patients with vitiligo","author":"Ganesan","year":"2026","journal-title":"J Invest Dermatol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00403-024-03658-x","article-title":"Repigmentation in non-segmental vitiligo using the Janus kinase inhibitor upadacitinib, a retrospective case series","volume":"317","author":"Zhu","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20109","article-title":"Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid-resistant vitiligo: A prospective case series","volume":"39","author":"Zhu","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.01.033","article-title":"Upadacitinib and its role in the treatment of vitiligo: A new possible therapeutic perspective","volume":"46","author":"Magdaleno-Tapial","year":"2024","journal-title":"JAAD Case Rep"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.07.1016","article-title":"Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo","volume":"89","author":"Su","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20565","article-title":"Treatment of refractory progressive vitiligo with oral upadacitinib and narrow-band ultraviolet-B: A case series","volume":"39","author":"Yue","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2492879","article-title":"Clinical observation of 10 cases of stable non-segmental vitiligo in adults treated with upadacitinib","volume":"36","author":"Yuan","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2025.04.014","article-title":"Efficacy and safety of oral upadacitinib-topical ruxolitinib combination therapy in the treatment of progressive nonsegmental vitiligo","volume":"22","author":"Li","year":"2025","journal-title":"JAAD Int"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2200873","article-title":"Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report","volume":"34","author":"Pan","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1159\/000544703","article-title":"Upadacitinib monotherapy in vitiligo associated with atopic dermatitis: Killing two birds with one stone","volume":"17","author":"Magnanimi","year":"2025","journal-title":"Case Rep Dermatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.s467026","article-title":"Treatment of refractory segmental vitiligo and alopecia areata in a child with upadacitinib and NB-UVB: A case report","volume":"17","author":"Mu","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.05.078","article-title":"A prospective observational study of oral abrocitinib and narrow-band ultraviolet-B in refractory progressive vitiligo","volume":"91","author":"Xu","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2574307","article-title":"Long-term efficacy and safety of oral abrocitinib combined with narrow-band UVB phototherapy in non-segmental vitiligo: a 52-week prospective study","volume":"36","author":"Xu","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2050313X241231527","DOI":"10.1177\/2050313x241231527","article-title":"Rapid resolution of non-segmental vitiligo in a patient treated with abrocitinib: A case report","volume":"12","author":"Satkunanathan","year":"2024","journal-title":"SAGE Open Med Case Rep"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.2147\/jaa.s492614","article-title":"Concurrent refractory atopic dermatitis and generalized vitiligo successfully treated with abrocitinib: A case report","volume":"17","author":"Shao","year":"2024","journal-title":"J Asthma Allergy"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2528344","article-title":"Vitiligo exacerbation during upadacitinib treatment for atopic dermatitis and improvement following a switch to abrocitinib: a case report","volume":"36","author":"Wang","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00701-3","article-title":"JAK in the [Black] box: A dermatology perspective on systemic JAK inhibitor safety","volume":"23","author":"Elmariah","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.004","article-title":"Janus kinase inhibitors in dermatology: A systematic review","volume":"76","author":"Shreberk-Hassidim","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00840-1","article-title":"Real-world use of ruxolitinib cream: Safety analysis at 1 year","volume":"25","author":"Hu","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01555-3","article-title":"Long-term integrated safety summary of ruxolitinib cream in phase 3 clinical trials of patients with vitiligo","volume":"15","author":"Rosmarin","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.05.002","article-title":"Association of myalgias with compounded topical Janus kinase inhibitor use in vitiligo","volume":"6","author":"Narla","year":"2020","journal-title":"JAAD Case Rep"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf519","article-title":"Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study","volume":"194","author":"Harris","year":"2026","journal-title":"Br J Dermatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.21417\/b7v884","article-title":"Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo","volume":"139","author":"Richmond","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2016.11.005","article-title":"Segmental vitiligo","volume":"35","author":"van Geel","year":"2017","journal-title":"Dermatol Clin"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100230","article-title":"Baseline levels of circulating inflammatory biomarkers stratify patients with vitiligo who significantly repigment after treatment with ruxolitinib cream","volume":"3","author":"Howell","year":"2023","journal-title":"JID Innov"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01223-y","article-title":"Psychometric evaluation of the facial and total vitiligo area scoring index instruments in the TRuE-V phase 3 studies","volume":"14","author":"Bibeau","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B91","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jamadermatol.2024.4534","article-title":"Psychometric properties and meaningful change thresholds of the vitiligo area scoring index","volume":"161","author":"Ezzedine","year":"2025","journal-title":"JAMA Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1868416\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:48:03Z","timestamp":1783403283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1868416\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":91,"alternative-id":["10.3389\/fimmu.2026.1868416"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1868416","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1868416"}}